Brain Scientific (OTCQB: BRSF), a neurology focused medical device and software company, recently announced a collaboration with JelikaLite, a company developing Cognilum(TM), a non-invasive wearable photobiomodulation device that is being developed to increase the well-being of children living with autism, through a clinical trial. In the trial, “Transcranial Photobiomodulation for Reducing Autism Symptoms in Children,” brain treatments for children diagnosed with autism would be delivered through Cognilum, while Brain Scientific’s NeuroEEG, a wireless EEG device, will monitor brain activity. The trial is designed to provide researchers and clinicians an opportunity to potentially uncover new treatment options for reducing the symptoms children with autism experience. “We are delighted to begin this collaboration with JelikaLite,” said Brain Scientific’s Director of Marketing, Irina Nazarova. “Our Neuro EEG solutions have a wide range of applications and helping to monitor children with autism to improve their well-being would be an important step towards a wider adoption of affordable and accessible EEG systems like ours.”
To view the full press release, visit https://ibn.fm/H9ses
About Brain Scientific
Brain Scientific is a commercial-stage health care company with two FDA-cleared products, providing next-gen solutions to the neurology market. The company’s smart diagnostic devices and sensors simplify administration, shorten scan time and cut costs, allowing clinicians to make rapid decisions remotely and bridge the widening gap in access to neurological care. To learn more about the company’s corporate strategy, devices or for investor relations, visit www.BrainScientific.com.
NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.investorwire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork.